×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AQST – aquestive therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AQST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
08:19 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
12/19
08:07 am
aqst
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five [Yahoo! Finance]
Low
Report
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five [Yahoo! Finance]
12/19
08:00 am
aqst
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
Low
Report
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
12/17
02:00 pm
aqst
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside [Yahoo! Finance]
Low
Report
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside [Yahoo! Finance]
12/17
08:54 am
aqst
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $17.00 price target on the stock.
12/17
06:10 am
aqst
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year [Yahoo! Finance]
Low
Report
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year [Yahoo! Finance]
12/2
08:07 am
aqst
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]
Medium
Report
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film [Yahoo! Finance]
12/2
08:00 am
aqst
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Medium
Report
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2024
04:36 pm
aqst
aquestive therapeutics, inc.
MISS
Report
-11.9%
aquestive therapeutics, inc.
8/6/2024
04:22 pm
aqst
aquestive therapeutics, inc.
BEAT
Report
-3.9%
aquestive therapeutics, inc.
5/7/2024
04:19 pm
aqst
aquestive therapeutics, inc.
MISS
Report
-6.8%
aquestive therapeutics, inc.
3/5/2024
05:05 pm
aqst
aquestive therapeutics, inc.
MISS
Report
11.3%
aquestive therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/19
08:03 am
aqst
Form 8-K Aquestive Therapeutics, For: Dec 19
Low
Report
Form 8-K Aquestive Therapeutics, For: Dec 19
12/4
04:47 pm
aqst
Form 4 Aquestive Therapeutics, For: Dec 02 Filed by: BRATTON DOUGLAS K
Low
Report
Form 4 Aquestive Therapeutics, For: Dec 02 Filed by: BRATTON DOUGLAS K
12/2
08:08 am
aqst
Form 8-K Aquestive Therapeutics, For: Dec 02
Medium
Report
Form 8-K Aquestive Therapeutics, For: Dec 02
11/27
04:24 pm
aqst
Form 4 Aquestive Therapeutics, For: Nov 26 Filed by: Jung Cassie
Low
Report
Form 4 Aquestive Therapeutics, For: Nov 26 Filed by: Jung Cassie
11/14
03:47 pm
aqst
Form SC 13G/A Aquestive Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G/A Aquestive Therapeutics, Filed by: ARMISTICE CAPITAL, LLC
11/8
05:32 pm
aqst
Form SC 13G Aquestive Therapeutics, Filed by: BlackRock, Inc.
Medium
Report
Form SC 13G Aquestive Therapeutics, Filed by: BlackRock, Inc.
11/7
04:02 pm
aqst
Form 8-K Aquestive Therapeutics, For: Nov 01
Medium
Report
Form 8-K Aquestive Therapeutics, For: Nov 01
11/6
04:02 pm
aqst
Form 8-K Aquestive Therapeutics, For: Nov 06
Low
Report
Form 8-K Aquestive Therapeutics, For: Nov 06
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/5
Form 8-K Aquestive Therapeutics, For: Nov 05
23.6%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
4/24 Form 8-K Aquestive Therapeutics, For: Apr 23 17.2%
2/10 Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film 17.0%
12/10 Form 424B5 Aquestive Therapeutics, 16.5%
4/5 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. 14.7%
8/6 Aquestive Therapeutics Announces Positive Topline Results from Libervant™ (Diazepam) Buccal Film Single Dose Crossover Study 11.7%
11/9 Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.8%
3/3 Form 4 Aquestive Therapeutics, For: Feb 29 Filed by: Kendall Keith J 10.7%
3/18 Form 4 Aquestive Therapeutics, For: Mar 16 Filed by: Boyd Peter E. 10.7%
7/2 Form 4 Aquestive Therapeutics, For: Jun 30 Filed by: Schobel Alexander Mark 8.3%
TOP News Decliners
3/11
Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.450 ActVsEst (0.030) - Miss
-40.0%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
1/12 Aquestive Therapeutics Receives FDA Response to Citizen’s Petition -33.9%
12/12 Aquestive Therapeutics Announces Pricing of Public Offering of Common Stock -19.7%
5/8 Q1/2019 3/31/2019 EPS -0.590 ZacksConsensus -0.490 ActVsEst (0.100) - Miss -17.1%
3/12 Aquestive Therapeutics, Inc. (AQST) Q4 2019 Earnings Call Transcript [The Motley Fool] -13.8%
3/15 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock. -13.0%
2/26 Form 4/A Aquestive Therapeutics, For: Nov 30 Filed by: Kendall Keith J -10.6%
12/27 Aquestive Therapeutics Inc (NASDAQ: AQST) had its "buy" rating re-affirmed by analysts at Lake Street Capital. They now have a $10.00 price target on the stock, down previously from $11.00. -9.9%
8/13 Form 4 Aquestive Therapeutics, For: Aug 09 Filed by: Wood Theresa -9.7%
5/20 Aquestive Therapeutics Inc (NASDAQ: AQST) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "sell" rating. -9.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: